Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells

Ekaterina Mikhailova; Olga Illarionova; Larisa Shelikhova; Elena Zerkalenkova; Olga Molostova; Yulia Olshanskaya; Galina Novichkova; Alexey Maschan; Michael Maschan; Alexander Popov

doi:10.3324/haematol.2021.279677

Immunophenotypic changes in leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia after treatment with CD19-directed chimeric antigen receptor (CAR)- expressing T cells

Haematologica. 2022 Apr 1;107(4):970-974. doi: 10.3324/haematol.2021.279677.

Affiliations

¹ Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation.
² Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation. [email protected].

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antigens, CD19
Child
Humans
Immunotherapy, Adoptive / adverse effects
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
Receptors, Antigen, T-Cell / genetics
Receptors, Chimeric Antigen* / genetics
T-Lymphocytes

Substances

Antigens, CD19
Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen

Grants and funding

Funding: the KMT2A rearrangement assessment study was supported by RFBR grant number 7-29-06052 and Presidential grant number MK-1645.2020.7 and 075-15-2020-338. Flow cytometric minimal residual disease evaluation was supported by RFBR grant number 18-29-09132.